Phase III
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
The pooled data results came five months after the FDA rejected Zynquista following a split advisory committee vote.
Tagrisso improved overall survival in lung cancer patients.
Boston-based Rhythm announced positive topline data from two Phase III clinical trials of setmelanotide, its melanocortin-4 receptor (MC4R) agonist. The trials evaluated the drug for the treatment of pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities.
AstraZeneca and Merck plan on seeking regulatory approval for Lynparza as a treatment for a subset of prostate cancer patients based on the Phase III PROfound data.
Basilea Pharmaceutica, based in Basel, Switzerland, announced positive topline data from its Phase III TARGET study of deftobiprole for acute bacterial skin and skin structure infections.
The two companies will seek approval for the biologic as a treatment for severe atopic dermatitis in children ages six to 11.
First patient enrolment at University of Cincinnati
Eli Lilly and Company reported that its Emgality met the primary and all key secondary endpoints in its Phase III CONQUER study for chronic and episodic migraine.
Roche announced interim results from its Phase III IMvigor130 clinical trial, indicating it met its co-primary endpoint of progression-free survival. The trial evaluated the combination of Tecentriq and platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma compared to chemotherapy alone.
PRESS RELEASES